유두상 갑상선 암 환자에서 수술 전 혈청 호중구-림프구 비의 임상적 의의
The Clinical Significance of Preoperative Serum Neutrophil-Lymphocyte Ratio (NLR) in Papillary Thyroid Cancer Patients
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose: Papillary thyroid cancer (PTC) is known to have a favorable prognosis and low mortality. However, some PTC has aggressive propensity with loco-regional recurrence or distant metastasis, and it could cause poor quality of life. Many studies for predicting high-risk group in papillary thyroid cancer have been reported, however, more study is needed. The objective of this study is to assess the efficiency of inflammation indices including the Neutrophil-Lymphocyte Ratio (NLR) as a predictor for high-risk group in papillary thyroid cancer patients. Methods: From January 2006 to November 2012, this study enrolled consecutive 164 patients who underwent total thyroidectomy and were confirmed with papillary thyroid cancer by histopathology. Among 164 patients, 23 were excluded because they had co-morbidities which could confound the inflammation related variables. We reviewed the medical records of 141 patients and assessed the correlation between inflammation indices including preoperative serum NLR and clinical prognostic parameters, including age at presentation, tumor size, extra-thyroidal extension, lymph node metastasis, TNM stage, and MACIS score. Results: In the papillary thyroid cancer patients, preoperative value of NLR, ESR, CRP, platelet, and albumin showed no significant correlation with the risk factors. Conclusion: In this study, preoperative inflammatory parameters such as NLR had uncertain efficacy as risk factors for papillary thyroid cancer.
Abstract
Purpose: Papillary thyroid cancer (PTC) is known to have a favorable prognosis and low mortality. However, some PTC has aggressive propensity with loco-regional recurrence or distant metastasis, and it could cause poor quality of life. Many studies for predicting high-risk group in papillary thyroid cancer have been reported, however, more study is needed. The objective of this study is to assess the efficiency of inflammation indices including the Neutrophil-Lymphocyte Ratio (NLR) as a predictor for high-risk group in papillary thyroid cancer patients. Methods: From January 2006 to November 2012, this study enrolled consecutive 164 patients who underwent total thyroidectomy and were confirmed with papillary thyroid cancer by histopathology. Among 164 patients, 23 were excluded because they had co-morbidities which could confound the inflammation related variables. We reviewed the medical records of 141 patients and assessed the correlation between inflammation indices including preoperative serum NLR and clinical prognostic parameters, including age at presentation, tumor size, extra-thyroidal extension, lymph node metastasis, TNM stage, and MACIS score. Results: In the papillary thyroid cancer patients, preoperative value of NLR, ESR, CRP, platelet, and albumin showed no significant correlation with the risk factors. Conclusion: In this study, preoperative inflammatory parameters such as NLR had uncertain efficacy as risk factors for papillary thyroid cancer.
참고문헌 (30)
- Davies L, "Current thyroid cancer trends in the United States", JAMA Otolaryngol Head Neck Surg, 140, pp.317~322 (2014)
- Kim SK, "Pyrosequencing analysis for detection of a BRAFV600E mutation in an FNAB specimen of thyroid nodules", Diagn Mol Pathol, 17, pp.118~125 (2008)
- Schlumberger MJ, "Papillary and follicular thyroid carcinoma", N Engl J Med, 338, pp.297~306 (1998)
- 안소은, "갑상선 유두미세암에서 중심 림프절 전이를 예측할 수 있는 인자에 관한 분석", 대한내분비외과학회지, 12(4), pp.252~257 (2012), 대한갑상선-내분비외과학회
- Dean DS, "Prognostic indicators in differentiated thyroid carcinoma", Cancer Control, 7, pp.229~239 (2000)
- Fiore E, "Serum TSH and risk of papillary thyroid cancer in nodular thyroid disease", J Clin Endocrinol Metab, 97, pp.1134~1145 (2012)
- Xing M, "Association between BRAF V600E mutation and mortality in patients with papillary thyroid cancer", JAMA, 309, pp.1493~1501 (2013)
- Jensen K, "Dynamic changes in E-cadherin gene promoter methylation during metastatic progression in papillary thyroid cancer", Exp Ther Med, 1, pp.457~462 (2010)
- Barbaro D, "The BRAF V600E mutation in papillary thyroid cancer with positive or suspected pre-surgical cytological finding is not associated with advanced stages or worse prognosis", Endocrine, 45, pp.462~468 (2014)
- Sansone P, "Environment, inflammation, and cancer", Curr Opin Genet Dev, 21, pp.80~85 (2011)
- Baniyash M, "Chronic inflammation and cancer: suppressing the suppressors", Cancer Immunol Immunother, 63, pp.11~20 (2014)
- 백광열, "Clinical Implications of Systemic Inflammatory Response Markers as Independent Prognostic Factors in Colorectal Cancer Patients", Cancer Research and Treatment, 46(1), pp.65~73 (2014), 대한암학회
- Wang W, "Poorer prognosis and higher prevalence of BRAF (V600E) mutation in synchronous bilateral papillary thyroid carcinoma", Ann Surg Oncol, 19, pp.31~36 (2012)
- Xing M, "BRAF mutation predicts a poorer clinical prognosis for papillary thyroid cancer", J Clin Endocrinol Metab, 90, pp.6373~6379 (2005)
- Zoghlami A, "BRAF mutation in papillary thyroid carcinoma:predictive value for long-term prognosis and radioiodine sensitivity", Eur Ann Otorhinolaryngol Head Neck Dis, 131, pp.7~13 (2014)
- Li C, "Does BRAF V600E mutation predict aggressive features in papillary thyroid cancer? Results from four endocrine surgery centers", J Clin Endocrinol Metab, 98, pp.3702~3712 (2013)
- Nakamura M, "E-cadherin expression and cell proliferation in the primary tumor and metastatic lymph nodes of papillary thyroid microcarcinoma", Mol Clin Oncol, 2, pp.226~232 (2014)
- Nam JK, "Is the BRAF(V600E) mutation useful as a predictor of preoperative risk in papillary thyroid cancer?", Am J Surg, 203, pp.436~441 (2012)
- Davis RB, "Comparative studies of blood coagulation and platelet aggregation in patients with cancer and nonmalignant diseases", Ann Intern Med, 71, pp.67~80 (1969)
- Ma X, "Prognostic significance of thrombocytosis, platelet parameters and aggregation rates in epithelial ovarian cancer", J Obstet Gynaecol Res, 40, pp.178~183 (2014)
- Shilova AN, "Changes of platelet aggregation in cancer patients", Vopr Onkol, 53, pp.722~723 (2007)
- Jurasz P, "Platelet--cancer interactions: mechanisms and pharmacology of tumour cell-induced platelet aggregation", Br J Pharmacol, 143, pp.819~826 (2004)
- Heinmoller E, "Studies on tumor-cell-induced platelet aggregation in human lung cancer cell lines", J Cancer Res Clin Oncol, 122, pp.735~744 (1996)
- Tsuruo T, "Cancer metastasis and platelet aggregation", Tanpakushitsu Kakusan Koso, 35, pp.2818~2824 (1990)
- Djaladat H, "The association of preoperative serum albumin level and American Society of Anesthesiologists (ASA) score on early complications and survival of patients undergoing radical cystectomy for urothelial bladder cancer", BJU Int, 113, pp.887~893 (2014)
- Lin MY, "Preoperative serum albumin but not prealbumin is an excellent predictor of postoperative complications and mortality in patients with gastrointestinal cancer", Am Surg, 77, pp.1286~1289 (2011)
- Asher V, "Preoperative serum albumin is an independent prognostic predictor of survival in ovarian cancer", Med Oncol, 29, pp.2005~2009 (2012)
- Sun LC, "Preoperative serum carcinoembryonic antigen, albumin and age are supplementary to UICC staging systems in predicting survival for colorectal cancer patients undergoing surgical treatment", BMC Cancer, 9, pp.288~ (2009)
- Lipschitz DA, "The correctability of the nutritional, immune, and hematopoietic manifestations of protein calorie malnutrition in the elderly", J Am Coll Nutr, 1, pp.17~25 (1982)
- Seretis C, "The significance of neutrophil", lymphocyte ratio as a possible marker of underlying papillary microcarcinomas in thyroidal goiters: a pilot study, 2013, pp.205, 691~696